The R&D collaboration has been established to investigate potential clinical candidates resulting from Acadia’s medicinal chemistry and discovery platform against a broad array of selective muscarinic receptors (receptors
The first approval granted Taxotere (docetaxel), in combination with doxorubicin and cyclophosphamide, for the adjuvant treatment of patients with operable node-positive breast cancer. A second granted Taxotere, in
“Through this collaboration, we intend to leverage the skills and strengths of both companies to develop novel antibodies for an important clinical indication where there is significant unmet
This multi-center, multi-national study is designed to assess the effectiveness of Mylinax (a proprietary oral formulation of cladribine) in patients with relapsing forms of multiple sclerosis. Endpoints will
The trial, named VISTA, will evaluate Velcade (bortezomib) in combination with melphalan and prednisone versus melphalan and prednisone in patients with newly diagnosed multiple myeloma (MM) who are
In the small safety and immunogenicity study, there was a 36% reduction in median time from administration of the drug to hospital discharge in the Altastaph-treated patients, as
Chugai will use Xencor’s XmAb technology on its antibodies against a cancer target. The XmAb technology consists of a suite of engineered antibody Fc domains that can be
The collaboration between Exelixis and GlaxoSmithKline was established in October 2002 to discover and develop novel therapeutics in the areas of vascular biology, inflammatory disease and oncology. Under
TRU-015 is designed to deplete B lymphocytes and is the first small modular immunopharmaceutical (SMIP) to enter a phase I study. SMIP product candidates utilize key structures –
The project is headed by DVC, the prime systems contractor for the Department of Defense Joint Vaccine Acquisition Program (JVAP), with ID Biomedical serving as the manufacturing development
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.